Hello, I have just been diagnosed with Stage C liver cancer and been put on NEXAVAR. I am into week 3 now and have several side effects and some are changing as the weeks progress. I am basically exhausted all the time and not feeling like eating obviously does not help! I would be very grateful if anybody can tell me how long it takes to become acclimatized with the drug, if one ever does! Any help or advise would be great, thanks!
Hi and welcome to the Online Community.
I am so sorry to read about your Liver Cancer diagnosis but I am sure you will find the support available in the community helpful at this difficult time.
Cancer treatments across cancer types can be rather different so talking with others who are walking the same type of cancer treatment journey (my one is completely different) will help you navigate this challenging time.
The New to Community is like the Community Reception area and as there are many cancer types and experiences so likewise the Community has many support groups but I see you have joined our supportive Liver cancer group as this will be a good place for you to connect with other folks who may be on the same cancer treatment support pathway.
Navigating the community will depend on the device you are using. To go to the group just click on the green link above then introduce yourself by putting up a post by clicking on ‘New Thread’ or ‘New here, say hello’ then hit the box with the X on the top right (phones).
You could just copy and paste the text from this your first post and you can also join in with existing ‘Discussions’ by clicking on 'reply'.
It’s always good to talk so do call the Macmillan Support Services on 0808 808 00 00 - most services are open 8am to 8pm, 7 days a week Clicking here to see what is available. This service provides lots of cancer information, support, financial guidance or just a listening ear.
To find information covering diagnosis, treatments and pages covering most types of cancers check our Online Information and Support Section.
All the very best.
